

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (East), Mumbai 400 098

[Tel:+91-22-26541851/55](tel:+91-22-26541851/55) [Fax:+91-22-26520787](tel:+91-22-26520787) [Email compliance.officer@indoco.com](mailto:compliance.officer@indoco.com)

Web:www.indoco.com CIN:L85190MH1947PLC005913

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2016

(₹ In Lakhs)

Sr. No	Particulars	Quarter ended 31.12.2016 (Unaudited)	Quarter ended 30.09.2016 (Unaudited)	Quarter ended 31.12.2015 (Unaudited)	Nine months ended 31.12.2016 (Unaudited)	Nine months ended 31.12.2015 (Unaudited)	Year ended 31.03.2016 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from operations	27,221	27,639	25,641	80,110	72,301	98,212
	(b) Other Operating Income	598	462	402	1,525	1,871	2,677
	Total Income from Operations (Net) (a+b)	27,819	28,101	26,043	81,635	74,172	1,00,889
2	Expenses						
	(a) Cost of materials consumed	6,916	7,864	8,623	21,879	23,210	30,411
	(b) Purchases of stock-in-trade	1,649	2,908	1,559	6,338	4,662	5,608
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,263	(1,065)	(704)	224	(1,461)	(1,078)
	(d) Employee Benefits expense	5,507	5,341	4,467	15,922	13,011	18,217
	(e) Depreciation and Amortisation expense	1,438	1,668	1,523	4,786	4,509	6,034
	(f) Research & Development Expense	1,382	1,204	1,104	3,785	2,996	4,318
	(g) Other Expenses	7,149	7,654	6,718	21,159	18,739	26,178
	Total Expenses	25,304	25,574	23,290	74,093	65,666	89,688
3	Profit from Operations before Other Income, Finance costs and Exceptional Items (1-2)	2,515	2,527	2,753	7,542	8,506	11,201
4	Other Income	114	102	20	247	65	119
5	Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)	2,629	2,629	2,773	7,789	8,571	11,320
6	Finance Costs	293	157	562	694	969	1,227
7	Profit from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)	2,336	2,472	2,211	7,095	7,602	10,093
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7- 8)	2,336	2,472	2,211	7,095	7,602	10,093
10	Tax Expenses	577	259	313	1,144	1,468	1,761
11	Net Profit from Ordinary Activities after Tax (9-10)	1,759	2,213	1,898	5,951	6,134	8,332
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	1,759	2,213	1,898	5,951	6,134	8,332
14	Other Comprehensive Income (after tax)	(3)	-	(4)	(10)	(10)	-
15	Total Comprehensive Income (after tax) (OCI) (13+14)	1,756	2,213	1,894	5,941	6,124	8,332
16	Paid up Equity Share Capital (Face value ₹2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
17	Reserves excluding Revaluation Reserves as per Balance Sheet of Previous accounting year						56,579
18	Earnings per share (before and after extraordinary items) (of ₹ 2/- each) (not annualised):						
	(a) Basic	1.91	2.40	2.06	6.45	6.65	9.04
	(b) Diluted	1.91	2.40	2.06	6.45	6.65	9.04

Notes :

- 1 The company adopted Indian accounting Standards (" Ind AS ") from 1st April, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial results for all the periods except year ended 31st March, 2016 presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2 There is a possibility that these quarterly financial results along with the provisional financial statements as of and for the year ended 31st March, 2016 may require adjustment before constituting the final Ind AS financial statements as of and for the year ended 31st March, 2017 due to changes in financial reporting requirements arising from the new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application of certain Ind AS as permitted under Ind AS 101.

3 In accordance with SEBI circular no.CIR/CFD/FAC/62/2016 dated 5th July ,2016 Financial results for :
 (a) Three months and nine months ended 31st December, 2016 and Three months ended 30th September,2016 are as per notified Ind-AS
 (b) Three months and nine months ended 31st December, 2015 are recast as per Ind-AS, the limited review of which is not carried out by the Statutory Auditors. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the affairs.
 (c) Year ended 31st March, 2016 are prepared as per previous Indian GAAP.

4 (a) Reconciliation between the profits as reported earlier and recast as per Ind AS for the three months and nine months ended 31st Dec, 2015

(₹ In Lakhs)

Particulars	Quarter ended 31.12.2015 (Unaudited)	Nine months ended 31.12.2015 (Unaudited)
Net Profit after tax reported earlier	2,042	6,331
Add:		
Net Sales/Income Adjustments	(39)	(140)
Finance Cost	(279)	(208)
Employee Benefit Expenses	-	1
	(318)	(347)
Less:		
Tax Expenses	174	150
	174	150
Net Profit recast to Ind AS for the three months and nine months ended 31st Dec, 2015	1,898	6,134

(b) Reconciliation of Total Comprehensive Income (OCI) for three months and nine months ended 31st Dec, 2015

(₹ In Lakhs)

Particulars	Quarter ended 31.12.2015 (Unaudited)	Nine months ended 31.12.2015 (Unaudited)
Net Profit recast to Ind AS for the three months and nine months ended 31st Dec, 2015	1,898	6,134
Other comprehensive income after tax	(4)	(10)
Total Comprehensive Income after tax for the three months and nine months ended 31st Dec, 2015	1,894	6,124

5 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

6 **Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:** (₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 31.12.2016 (Unaudited)	Quarter ended 30.09.2016 (Unaudited)	Quarter ended 31.12.2015 (Unaudited)	Nine months ended 31.12.2016 (Unaudited)	Nine months ended 31.12.2015 (Unaudited)	Year ended 31.03.2016 (Audited)
India	15,213	18,108	14,430	48,918	42,607	56,743
Outside India	12,008	9,531	11,211	31,192	29,694	41,469
Total	27,221	27,639	25,641	80,110	72,301	98,212

7 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 27th Jan, 2017. The Statutory Auditors have carried out a limited review of the results for the three months ended 31st Dec, 2016.

8 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board
For Indoco Remedies Ltd

sd/-
Suresh G. Kare
Chairman

Place : Mumbai
Date : 27th January, 2017.